Bristol-Myers Squibb Co


  • Feb 10- U.S. Food and Drug Administration reviewers are divided on whether an intravenous blood clot preventer developed by The Medicines Co should be approved, news that sent the company's stock down more than 7 percent on Monday.

  • *Q4 sales $6.84 bln vs consensus $6.88 bln. *Q4 core earnings per share $1.23 vs consensus $1.16. LONDON, Feb 6- AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from late May.

  • *Q4 core earnings per share $1.23 vs $1.16. LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Shares in AstraZeneca fell 1 percent in early trading.

  • Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.

  • INTERVIEW-Lilly CEO: 'It's time to go back on offense' Wednesday, 29 Jan 2014 | 3:50 PM ET

    Jan 29- After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.

  • US bond prices rise on China, Argentina jitters Friday, 24 Jan 2014 | 2:31 PM ET

    U.S. bonds pushed higher on Friday, after disappointing manufacturing data from both the U.S. and China revived the safe haven bid for Treasurys.

  • Jan 24- Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.

  • Midday movers: KSU, .DJT & More Friday, 24 Jan 2014 | 12:32 PM ET
    United Airlines planes at San Francisco International Airport

    Friday's midday movers:

  • Traders pondering if this US selloff is the big one Friday, 24 Jan 2014 | 11:38 AM ET
    A trader works on the floor of the New York Stock Exchange in New York, on Friday, Jan. 24, 2014.

    U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.

  • Cramer: How to deal with Wall Street selloff Friday, 24 Jan 2014 | 10:10 AM ET

    CNBC's Jim Cramer offers some simple advice on how to deal with the Wall Street selloff.

  • *Knocks back Teva's Nerventra and Novartis' serelaxin. LONDON, Jan 24- Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan.

  • US stocks setting up for another steep loss Friday, 24 Jan 2014 | 8:28 AM ET

    U.S. stock index futures pointed to another steep loss on Friday, with European and Asian shares trading lower.

  • UPDATE 1-GSK diabetes drug set for European approval Friday, 24 Jan 2014 | 8:25 AM ET

    LONDON, Jan 24- GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca.

  • UPDATE 1-Bristol-Myers beats sales, profit forecasts Friday, 24 Jan 2014 | 8:04 AM ET

    Jan 24- Bristol-Myers Squibb Co's quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer, blood clots and diabetes. The company on Friday said it earned $726 million, or 44 cents per share, in the fourth quarter.

  • As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.

  • Game plan: 16 earnings Cramer wouldn't miss Friday, 17 Jan 2014 | 6:03 PM ET

    With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?

  • Jan 15- Merck& Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not bound to follow the advice of its advisory panels but typically does so.

  • Lightning Round: Starbucks, GE & More Tuesday, 14 Jan 2014 | 6:37 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • WASHINGTON, Jan 14- The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson& Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have recently suffered a heart attack.

  • *Shares in AstraZeneca rise 2 percent. LONDON, Jan 14- AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.

Most Popular Video

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.

Thursday, 17 Apr 2014 | 11:40 AM ET

CNBC's Dominic Chu and Art Cashin, of UBS, discuss market fluctuations over the last week, as well as the credible reversal rally. He's still keeping an eye on Ukraine, and says there may be economic fallout if there are new sanctions against Russia.

Thursday, 17 Apr 2014 | 12:09 PM ET

CNBC's Scott Cohn reports Hampshire Hotel CEO Sant Singh Chatwal pleaded guilty in a campaign scheme.